GelStat(OTC) GSAC

Market Cap$1.12M

Since IPO (2003)-100%

5 Year-98%

1 Year-25%

1 Month+0%

$0.00

+0.00%

+0.00Today

GelStat last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-10-06

GelStat stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-09-29
1 month	+0%	USD 0.00	2026-09-04
3 month	+0%	USD 0.00	2026-07-06
Year to date	-14.29%	USD 0.00	2025-12-31
1 year	-25%	USD 0.00	2025-10-06
3 year	+0%	USD 0.00	2023-10-06
5 year	-98.42%	USD 0.02	2021-10-06
Since inception	-99.95%	USD 0.60	2003-04-30

GelStat Financials at a Glance

Market Cap

$1.12M

Revenue (TTM)

$379.09K

Net Income (TTM)

-$278.06K

EPS (TTM)

-$0.00

P/E Ratio

-3.00

Dividend

$0.00

Beta (Volatility)

0.21 (Low)

Dividend

$0.00

Beta (Volatility)

0.21 (Low)

Price

$0.00

Volume

5,003,449

Open

$0.00

Price

$0.00

Volume

5,003,449

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Apr 16, 2015

Dividend

$0.00

Beta (Volatility)

0.21 (Low)

Price

$0.00

Volume

5,003,449

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Apr 16, 2015

GSAC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GelStat

GelStat Corporation operates as a consumer healthcare enterprise, specializing in the innovation, formulation, and commercialization of over-the-counter (OTC) health solutions. The company offers a diverse product portfolio that addresses various common health concerns.

Products and Services

GelStat Migraine, a patented remedy for migraine headache pain
Chews 2 Lose, an appetite-controlling gum for weight management
GelStat Sleep, designed to alleviate sleep disturbances

Growth Outlook

Recent quarterly revenue increased to $80,081, showing growth potential
Gross profit margin improved to 86.37% in Q2 2025
Expansion of distribution channels enhances market reach

Financial Highlights

Trailing twelve months (TTM) revenue of $246,000 indicates steady performance
Net income for Q2 2025 was -$99,982, reflecting ongoing challenges
Current ratio of 0.24 suggests liquidity concerns

GelStat Corporation is positioned in the healthcare sector, focusing on innovative solutions for common health issues. The company's product offerings, including GelStat Migraine and Chews 2 Lose, cater to significant consumer needs, which may drive future growth. Recent financial data indicates a revenue increase, although challenges remain evident in net income and liquidity ratios. The company’s strategic expansion of distribution channels could further enhance its market presence, making it an intriguing option for potential investors.

AI Generated • Oct 5, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Javier G. Acosta

Website

www.gelstat.com

Headquarters

Palm City, FL 34990, US

GSAC Financials

Key Financial Metrics (TTM)

Gross Margin

-47.68%

Operating Margin

-90.26%

Net Income Margin

-121.87%

Return on Equity

28.42%

Return on Capital

N/A

Return on Assets

-121.14%

Earnings Yield

-33.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.12M

Shares Outstanding

3.74B

Volume

5.00M

Avg. Volume

297.10K

Financials (TTM)

Gross Profit

$266.69K

Operating Income

-$430.82K

EBITDA

-$133.82K

Operating Cash Flow

-$39.70K

Capital Expenditure

$0.00

Free Cash Flow

-$39.70K

Cash & ST Invst.

$71.41K

Total Debt

$849.62K

GelStat Performance Analysis

GelStat annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 2,333	-66.8%
2023	2023-12-31	USD 149,527	6309.2%
2024	2024-12-31	USD 349,730	133.9%
2025	2025-12-31	USD 267,962	-23.4%

GelStat sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2024-09-30	50.5%
Q4	2024-12-31	N/A
Q1	2025-03-31	-45.0%
Q2	2025-06-30	24.1%

GelStat annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.00	33.3%
2023	2023-12-31	USD -0.00	-83.3%
2024	2024-12-31	USD -0.00	-50.0%
2025	2025-12-31	USD -0.00	0.0%

GelStat sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2024-09-30	N/A
Q4	2024-12-31	N/A
Q1	2025-03-31	N/A
Q2	2025-06-30	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2025YOY CHG

Revenue

$80.08K

+2.8%

Gross Profit

$69.16K

+20.4%

Gross Margin

86.37%

N/A

Market Cap

$1.12M

N/A

Market Cap/Employee

$561.05K

N/A

Employees

N/A

Net Income

-$99.98K

-120.2%

EBITDA

-$62.18K

-526.5%

Quarterly Fundamentals

Name

Q2 2025YOY CHG

Total Cash

$71.41K

+970.3%

Total Debt

$849.62K

+42.4%

Accounts Receivable

$45.59K

-0.7%

Inventory

$0.00

N/A

Long Term Debt

$781.97K

+109.7%

Short Term Debt

$67.66K

-69.8%

Return on Assets

-1.21%

N/A

Return on Invested Capital

50.71%

N/A

Free Cash Flow

-$15.49K

+36.0%

Operating Cash Flow

-$15.49K

+36.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AOXGAoxing Pharmaceutical Company, Inc.

AOXGAoxing Pharmaceutical Company, Inc.$0.00+0.00%

SFLMSFLMaven Corp.

SFLMSFLMaven Corp.$0.00+0.00%

GPFTGrapefruit USA, Inc.

GPFTGrapefruit USA, Inc.$0.00+20.00%

VDRMViaDerma, Inc.

VDRMViaDerma, Inc.$0.00+0.00%

LRSVLink Reservations Inc.

LRSVLink Reservations Inc.$0.00+0.00%

RLBDReal Brands, Inc.

RLBDReal Brands, Inc.$0.00+0.00%

PZOOPazoo, Inc.

PZOOPazoo, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$98.44+5.09%

CRWVCoreWeave

CRWVCoreWeave$59.65-2.83%

INTCIntel

INTCIntel$92.09+2.49%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$46.74-5.06%

NVDANvidia

NVDANvidia$217.10+1.39%

SLNSilence Therapeutics Plc

SLNSilence Therapeutics Plc$19.58+125.58%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$14.13+16.59%

Questions About GSAC

What is the current price of GelStat?

GelStat is trading at $0.00 per share.

What is the 52-week range for GelStat?

Over the past 52 weeks, GelStat has traded between $0.00 and $0.00.

How much debt does GelStat have?

As of the most recent reporting period, GelStat reported total debt of $853.41K.

How much cash does GelStat have on hand?

GelStat reported $3.96K in cash and cash equivalents in its most recent financial results.

What is GelStat’s dividend yield?

GelStat does not currently have a dividend yield.

GelStat(OTC) GSAC

GelStat Financials at a Glance

GSAC News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About GelStat

GSAC Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

GelStat Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About GSAC

What is the current price of GelStat?

What is the 52-week range for GelStat?

How much debt does GelStat have?

How much cash does GelStat have on hand?

What is GelStat’s dividend yield?

Premium Investing Services